Icad inc (ICAD)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flow from operating activities:
Net loss

-13,551

-9,017

-14,256

-10,099

-

-

-

-

-

-

-

Net loss

-

-

-

-

-32,447

-1,009

-7,608

-9,374

-37,587

-6,224

-1,968

Adjustments to reconcile net loss to net cash used for operating activities:
Amortization

377

383

494

983

1,768

2,270

1,724

1,904

2,094

1,167

1,170

Depreciation

297

325

995

1,322

1,580

1,256

706

891

1,077

476

751

Bad debt provision

62

225

45

177

383

167

35

-

-

-

-

Inventory obsolescence reserve

-

-

1,052

114

55

-

-

-

-

-

-

Stock-based compensation expense

1,169

1,505

3,656

2,307

2,135

1,318

1,202

996

904

1,516

1,994

Amortization of debt discount and debt costs

149

170

-

-23

341

1,246

-

-

-

-

-

Loss on extinguishment of debt

-

-

-

-

-1,723

-903

-

-

-

-

-

Gain from acquisition settlement

-

-

-

249

-

-

-

-

-

-

-

Goodwill and long-lived asset impairment

-

-

6,693

-

27,443

-

-

-

-

-

-

Amortization of debt discount and debt costs

-

-

-

-

-

-

856

1,012

-

-

-

Interest on settlement obligations

-

-

26

82

146

206

266

388

422

-

-

Deferred tax expense

1

-12

8

7

-

-

-

-

-

-

-

Loss on indemnification asset

-

-

-

-

-

-

-

-

741

-

-

Loss (gain) from change in fair value of warrant liability

-

-

-

-

-

-1,835

2,448

539

0

-

-

Gain on sale of patent

-

-

-

-

-

-

-

-

-

275

-

Goodwill impairment

-

-

-

-

-

-

-

-

26,828

-

-

Loss on disposal of assets

-

-12

-52

-10

-125

-

-53

-174

-21

-

-

Gain on sale of MRI assets

-

-

2,158

-

-

-

-

-

-

-

-

Change in fair value of convertible debentures

6,671

-

-

-

-

-

-

-

-

-

-

Fair value of contingent consideration

-

-

-

-

-

-

-

-

-4,900

-

-

Changes in operating assets and liabilities:
Accounts receivable

3,478

-2,003

3,474

-2,201

-1,772

840

2,678

976

614

-1,914

-878

Inventory

1,024

-536

-554

-482

2,042

323

-228

79

-1,449

-278

-354

Prepaid and other current assets

-294

-172

-29

504

197

-11

126

-469

-248

-78

-58

Accounts payable

836

-209

-215

-16

-557

150

60

815

-1,375

125

-824

Accrued expenses

982

494

-505

309

-2,060

296

-609

-1,775

-713

446

-530

Deferred revenue

108

-454

-333

-2,581

-2,068

-612

2,010

812

1,263

706

1,559

Total adjustments

6,444

5,150

6,919

4,621

30,547

4,213

6,175

5,170

27,445

6,431

5,410

Net cash used for operating activities

-

-

-

-

-1,900

3,204

-1,433

-4,204

-

-

-

Net cash used for operating activities

-7,107

-3,867

-7,337

-5,478

-

-

-

-

-10,142

207

3,442

Cash flow from investing activities:
Additions to patents, technology and other

10

15

5

12

40

50

168

70

13

28

138

Additions to property and equipment

296

301

390

337

932

1,214

539

665

263

322

173

Acquisition of VuComp M-Vu CAD

-

-

-

6

-

-

-

-

-

-

-

Sale of MRI assets

-

-

2,850

-

-

-

-

-

-

-

-

Proceeds from sale of patent

-

-

-

-

-

-

-

-

-

275

-

Acquisition

-

-

-

-

-

-

-

-

-

24

-

Net cash (used for) provided by investing activities

-

-

-

-

-2,672

-4,746

-707

-735

-

-

-

Net cash used for investing activities

-306

-316

2,455

-355

-

-

-

-

-276

-99

-311

Cash flow from financing activities:
Issuance of common stock for cash, net

9,353

-

-

0

0

28,214

-

-

60

-

23

Stock option exercises

1,400

204

79

198

366

708

146

-

-

-

-

Proceeds from convertible debentures

-

6,970

-

-

-

-

-

-

-

-

-

Principal payments of capital lease obligations

16

13

80

946

1,397

655

46

-

-

-

-

Principal repayment of debt financing

-2,000

-

6,000

-

-

-

-

-

-

-

-

Proceeds from debt financing

-

-

-

-

-

-

-

14,325

-

-

-

Principal repayment of debt financing, net

-

-

-

-

11,250

7,850

-

-

-

-

-

Proceeds from Line of Credit

3,000

-

-

-

-

-

-

-

-

-

-

Repayment of line of credit

1,000

-

-

-

-

-

-

-

-

-

-

Warrant exercise

-

-

-

-

-

1,575

-

-

-

-

-

Taxes paid related to restricted stock issuance

196

180

241

114

87

110

28

14

67

87

22

Debt issuance costs

-

-

74

-

-

-

-

-

-

-

-

Net cash used for financing activities

-

-

-

-

-12,368

21,882

72

14,311

-

-

-

Payment for Xoft

-

-

-

-

-

-

-

-

1,268

-

-

Net cash provided by financing activities

10,541

6,981

5,684

-862

-

-

-

-

-1,275

-87

1

Decrease in cash and equivalents

3,128

2,798

802

-6,695

-

-

-

-

-

-

-

(Decrease) increase in cash and equivalents

-

-

-

-

-16,940

20,340

-2,068

9,372

-11,693

21

3,132

Supplemental disclosure of cash flow information:
Interest paid

-

-

-

-

558

1,637

2,163

1,516

-

2

9

Interest paid

643

294

79

70

-

-

-

-

-

-

-

Taxes paid

43

51

60

67

128

157

78

55

40

89

95

Right-of-use assets obtained in exchange for new operating lease liabilities

3,105

-

-

-

-

-

-

-

-

-

-

Escrow due from MRI asset sale

-

-

350

-

-

-

-

-

-

-

-

Equipment purchased under capital lease

-

-

42

-

-

-

409

-

-

-

-

Settlement of warrant liability with purchase of common stock

-

-

-

-

-

2,151

-

-

-

-

-

Issuance of common stock related to acquisition of Radion, Inc and DermEbx

-

-

-

-

-

8,556

-

-

-

-

-

Return of common stock from escrow related to acquisition of Xoft in 2011 and CAD Sciences in 2008.

-

-

-

-

-

-

-

-

-

-

11,000

Fair market value of iCAD common stock issued to acquire Xoft, Inc. and accrued cash consideration

-

-

-

-

-

-

-

-

-

12,668

-